SCHEMBL2929377

SCHEMBL2929377

CN(C)Cc1ccc2cc(NC(=O)c3ccc(-c4ccc(Cl)cc4)cc3)ccc2c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 13/20 0.60
MEN1 O00255 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
KMT2A Q03164 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HTR2C P28335 2/20 0.50
PTPN1 P18031 1/20 0.48
LSS P48449 1/20 0.48
ABL1 P00519 1/20 0.48
F10 P00742 1/20 0.47
KLKB1 P03952 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
ROCK2 O75116 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928407 0.93 MCHR1 (0.54) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL2928350 0.87 MEN1 (0.55) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL6308562 0.87 MCHR1 (0.58) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL6305345 0.86 MCHR1 (0.52) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL5645754 0.85 MCHR1 (0.68) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL13177428 0.85 NPC1 (0.52) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL2925645 0.85 MCHR1 (0.55) MCHR1NPC1RAB9AHTR2CF10
SCHEMBL2925533 0.82 MCHR1 (0.56) MCHR1MEN1NPC1RAB9AKMT2A
SCHEMBL2919360 0.78 MCHR1 (0.80) MCHR1NPC1RAB9AHTR2C
SCHEMBL2926522 0.77 MCHR1 (0.78) MCHR1NPC1RAB9AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US claimed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP claimed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885MEN1 292/4885NPC1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.